Association of response endpoints with survival outcomes in multiple myeloma

por Lonial, S, Anderson, K C
Publicado 2014

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

por Chauhan, D, Hideshima, T, Anderson, K C
Publicado 2006

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib

por Jagannathan, S, Vad, N, Vallabhapurapu, S, Vallabhapurapu, S, Anderson, K C, Driscoll, J J
Publicado 2015

Restoration of p16(INK4A) protein induces myogenic differentiation in RD rhabdomyosarcoma cells

por Urashima, M, Teoh, G, Akiyama, M, Yuza, Y, Anderson, K C, Maekawa, K
Publicado 1999

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib

por Jagannathan, S, Abdel-Malek, M A Y, Malek, E, Vad, N, Latif, T, Anderson, K C, Driscoll, J J
Publicado 2015

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu

por Zhang, L, Tai, Y-T, Ho, M, Xing, L, Chauhan, D, Gang, A, Qiu, L, Anderson, K C
Publicado 2017

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice

por Hu, Y, Zheng, M, Gali, R, Tian, Z, Topal Görgün, G, Munshi, N C, Mitsiades, C S, Anderson, K C
Publicado 2013

HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells

por Song, W, Tai, Y-T, Tian, Z, Hideshima, T, Chauhan, D, Nanjappa, P, Exley, M A, Anderson, K C, Munshi, N C
Publicado 2010

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

por Hideshima, T, Cottini, F, Ohguchi, H, Jakubikova, J, Gorgun, G, Mimura, N, Tai, Y-T, Munshi, N C, Richardson, P G, Anderson, K C
Publicado 2015

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

por Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Publicado 2014

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

por Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Publicado 2014

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Publicado 2018

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., Anderson, K. C.
Publicado 2019

P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C-MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES

por Yao, Y., Fong Ng, J., Park, W. D., Gramegna, D., Samur, A., Samur, M., Morelli, E., Chesi, M., Mitsiades, C., Anderson, K. C., Lin, C., Munshi, N., Fulciniti, M.
Publicado 2022

Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma

por Malek, E, Abdel-Malek, M A Y, Jagannathan, S, Vad, N, Karns, R, Jegga, A G, Broyl, A, van Duin, M, Sonneveld, P, Cottini, F, Anderson, K C, Driscoll, J J
Publicado 2017

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

por Calimeri, T, Battista, E, Conforti, F, Neri, P, Di Martino, M T, Rossi, M, Foresta, U, Piro, E, Ferrara, F, Amorosi, A, Bahlis, N, Anderson, K C, Munshi, N, Tagliaferri, P, Causa, F, Tassone, P
Publicado 2011

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

por Bolli, N, Li, Y, Sathiaseelan, V, Raine, K, Jones, D, Ganly, P, Cocito, F, Bignell, G, Chapman, M A, Sperling, A S, Anderson, K C, Avet-Loiseau, H, Minvielle, S, Campbell, P J, Munshi, N C
Publicado 2016

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

por Morelli, E, Leone, E, Cantafio, M E Gallo, Di Martino, M T, Amodio, N, Biamonte, L, Gullà, A, Foresta, U, Pitari, M R, Botta, C, Rossi, M, Neri, A, Munshi, N C, Anderson, K C, Tagliaferri, P, Tassone, P
Publicado 2015

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth

por Fulciniti, M, Amodio, N, Bandi, R L, Cagnetta, A, Samur, M K, Acharya, C, Prabhala, R, D'Aquila, P, Bellizzi, D, Passarino, G, Adamia, S, Neri, A, Hunter, Z R, Treon, S P, Anderson, K C, Tassone, P, Munshi, N C
Publicado 2016

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

por Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Publicado 2017